Description: Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its product pipeline is PCS499, which is use for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on October 2, 2017 and is headquartered in Hanover, MD.
Home Page: www.processapharmaceuticals.com
PCSA Technical Analysis
7380 Coca Cola Drive
Hanover,
MD
21076
United States
Phone:
443 776 3133
Officers
| Name | Title |
|---|---|
| Dr. David Young Ph.D., Pharm.D. | Co-Founder, Pres, CEO & Director |
| Mr. Patrick Lin | Co-Founder, Chief Bus. & Strategy Officer |
| Dr. Sian E. Bigora Ph.D., Pharm.D. | Co-Founder & Chief Devel. Officer |
| Ms. Wendy J. Guy | Co-Founder, Chief Admin. Officer & Corp. Sec. |
| Mr. James H. Stanker | Chief Financial Officer |
| Mr. Robert Michael Floyd | Chief Operating Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.8273 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2017-10-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 15 |